CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Shares Acquired by AMH Equity Ltd

AMH Equity Ltd lifted its holdings in shares of CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) by 17.4% in the fourth quarter, HoldingsChannel reports. The firm owned 116,500 shares of the company’s stock after acquiring an additional 17,295 shares during the period. AMH Equity Ltd’s holdings in CollPlant Biotechnologies were worth $419,000 at the end of the most recent reporting period.

Separately, Villere ST Denis J & Co. LLC increased its position in CollPlant Biotechnologies by 24.4% during the third quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock worth $2,407,000 after buying an additional 95,000 shares in the last quarter. Hedge funds and other institutional investors own 21.69% of the company’s stock.

CollPlant Biotechnologies Stock Up 6.4 %

Shares of NASDAQ:CLGN opened at $3.51 on Thursday. The business has a fifty day simple moving average of $3.77 and a 200-day simple moving average of $4.22. CollPlant Biotechnologies Ltd. has a 52 week low of $3.20 and a 52 week high of $6.75. The company has a market cap of $40.21 million, a P/E ratio of -2.28 and a beta of 0.86.

CollPlant Biotechnologies (NASDAQ:CLGN) last announced its quarterly earnings data on Wednesday, November 27th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). CollPlant Biotechnologies had a negative return on equity of 77.05% and a negative net margin of 2,680.00%. During the same quarter in the previous year, the business earned ($0.38) EPS. Sell-side analysts expect that CollPlant Biotechnologies Ltd. will post -1.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CLGN has been the topic of several recent research reports. D. Boral Capital restated a “buy” rating and issued a $14.00 price objective on shares of CollPlant Biotechnologies in a research report on Wednesday, February 12th. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of CollPlant Biotechnologies in a research note on Friday, November 29th.

CollPlant Biotechnologies Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.